Milli-Mark® Anti-CD64-PE Antibody, clone 10.1

Description

• General description: CD64 is the high-affinity IgG Fc receptor belonging to the immunoglobulin supergene family (Guyre, 2002). CD64 is a 72 kDa glycoprotein which binds monomeric IgG (human IgG>>IgG>>>IgG4>>>IgG2 and mouse IgG3>IgG2a>>>IgG1, IgG2b). Three genes: FcγR1A, FcγR1B and FcγR1C, which have >98 percent identity at the nucleotide level, have been identified and mapped to chromosome 1, band q21.1 (Sun,1997)). The FcγR1A gene, which specified the high-affinity IgG receptor, encodes three C2-type Ig-like extracellular domains, a 21 amino acid transmembrane region, and a charge cytoplasmic tail of 61 amino acids (Sun, 1997)(van de Winkel,1993).
• Specificity: Antibody recognizes Human CD64 antigen.
• Immunogen: Human rheumatoid synovial fluid cells and monocytes.
• Application: Milli-Mark Anti-CD64-PE Antibody, clone 10.1 detects level of CD64 & has been published & validated for use in FC.
• Quality: Evaluated by flow cytometry using human PBMCs
• Target description: 72 kDa (Sun W, 1997)
• Physical form: Protein A purified
• Storage and Stability: Maintained refrigerated at 2-8°C from date of receipt. Protected from light in undiluted aliquots for 6 months from date of receipt.
• Analysis Note: ControlPBMC′s
• Other Notes: Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
• Legal Information: MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.